Pain And Inflammation After Cataract Surgery Therapeutics
1. Nevanac patent expiration
Treatment: Method of treating ocular inflammation
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5475034 | HARROW EYE | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
Jun, 2014
(11 years ago) | |
| US7834059 | HARROW EYE | Topical nepafenac formulations |
Jan, 2027
(1 year, 22 days from now) | |
| US8071648 | HARROW EYE | Topical nepafenac formulations |
Dec, 2025
(a month ago) | |
| US8324281 | HARROW EYE | Topical nepafenac formulations |
Dec, 2025
(a month ago) | |
Drugs and Companies using NEPAFENAC ingredient
Market Authorisation Date: 19 August, 2005
Dosage: SUSPENSION/DROPS
More Information on Dosage
NEVANAC family patents
